March 16, 2020 / 12:02 PM / 25 days ago

BRIEF-Can Fite Biopharma Ltd - Enrolled 7 Patients For Compassionate Use Program For Namodenoson In Treatment Of Hepatocellular Cancer

March 16 (Reuters) - Can Fite Biopharma Ltd:

* CAN FITE BIOPHARMA LTD - ENROLLED 7 PATIENTS FOR COMPASSIONATE USE PROGRAM FOR NAMODENOSON IN TREATMENT OF HEPATOCELLULAR CANCER

* CAN FITE BIOPHARMA LTD - RESULTS INDICATE NAMODENOSON HAS A GOOD SAFETY PROFILE AND IS WELL TOLERATED IN PATIENTS UNDER COMPASSIONATE USE

* CAN FITE BIOPHARMA - 2 PATIENTS FROM FORMER PHASE II STUDY STILL UNDERGOING NAMODENOSON TREATMENT, EACH WITH OVERALL SURVIVAL OF MORE THAN 2.5 YRS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below